HER2 overexpression: 8 (4.7%), and triple negative: 15 (8.9%). The luminal phenotype showed mild/moderate cellularity (40.4%) (OR = 7.12, 95% CI: 1.61-31.52), inconspicuous, present nucleoli (55.5%) (OR = 8.31, 95% CI: 2.36-29.19), and mild/moderate nuclear atypia (44.5%) (OR = 8.42, 95% CI: 1.90-37.25). Conclusion: The criteria that might indicate the luminal phenotype of breast carcinoma in FNAC were mild/ moderate cellularity, inconspicuous, present, and nonprominent nucleoli, and mild/moderate nuclear atypia.
into clinical practice still face some challenges, especially concerning early diagnosis [3] [4] [5] [6] . From a pathologist's perspective, morphological and immunohistochemical correlates -as provided by surrogate classification of molecular phenotypes -can be useful tools in the attempt to reach this goal [7] [8] [9] [10] .
Since its description by Martin and Ellis in 1930 [11] , fine-needle aspiration cytology (FNAC) has been a widely used and accepted method for obtaining samples for cytological diagnosis in various organs and is a primary procedure for the assessment of breast lumps. FNAC is a fast, low-cost technique, with great diagnostic accuracy and with minimum risks to patients [12] [13] [14] [15] . Well-fixed smears along with the cell blocks obtained are optimal adjuncts to perform ancillary techniques, such as immunocytochemistry and molecular tests [16] [17] [18] [19] . Moreover, FNAC has a great intrinsic potential (concerning cytomorphology) to supply additional information to the diagnosis of breast carcinoma for each case [17] [18] [19] , which has been used in attempt to predict molecular phenotypes of breast carcinomas [20] .
Gene expression profiling techniques are not the current standard in clinical practice, but, for nearly a decade, hormone receptor (HR) testing and determination of the human epidermal factor neu receptor (HER2) status has been a routine part of treatment planning [6, 21, 22] . In the meantime, the number of commercially offered multigene prognostic/prediction assays employed in clinical decision making has increased [2, 9] . There are two HR+ breast carcinomas (luminal A and B) and two HR-carcinomas (HER2+ and basal like). The molecular subtypes can be approximated by HR/HER2 status and Ki-67 index; i.e. luminal A (HR+/HER2-/low Ki-67 index), luminal B (HR+/HER2±/high Ki-67 index), HER2 overexpression (HR-/HER2+), and triple negative (HR-/ HER2-) [1, 5, [7] [8] [9] [10] . The basal phenotype is characterized by immunoreactivity for basal or myoepithelial cell markers by applying, in general, a combination of highmolecular-weight cytokeratins (CK5/CK6, CK14, and CK17) and epidermal growth factor receptors [23, 24] .
Cytomorphologically, the basal phenotype has been investigated and described due to its relation to hereditary breast carcinoma [20] . However, the luminal phenotype, despite being the most common and having better prognosis as well as targeted therapies under study, has not yet been characterized using specific cytological criteria. Using FNAC, we aimed to identify the luminal phenotype of breast carcinoma through the evaluation of cytological criteria recognized in routine practice, once it is relevant for guiding treatment and predicting survival.
Materials and Methods

Samples
This study was based on a review of preoperative FNAC samples obtained before the histological diagnosis of ductal or lobular invasive breast carcinoma of biopsy and mastectomy specimens from 237 patients treated at the Oncology Hospital Amaral Carvalho (Jaú, Brazil) from 2000 to 2009. FNAC samples were previously stained with Giemsa (direct air-drying fixation), hematoxylin and eosin (HE), and Papanicolaou (PAP) stains (immediate fixation in 95% alcohol). The initial result of cytological analysis in the laboratory of origin, based on the NIH Consensus Development Conference, was named the initial cytology result. FNAC samples were analyzed using a multiheaded microscope (Olympus ® BX50 
Immunohistochemical Assay
Cases were grouped using a conventional tissue microarray (TMA) technique in order to enable maximal standardization of parameters. Considering the use of aged paraffin-embedded tissue, for those at least 5 years old, new sections from the TMA blocks were obtained immediately before the immunohistochemical study, as recommended in the literature [27, 28] . TMA slides were tested for estrogen receptor (ER), progesterone receptor (PR), HER2, Ki-67, and E-cadherin using the streptavidin-biotin-peroxidase technique. Positive and negative controls were included in each reaction in order to guarantee the reliability of the assays. Antigen retrieval, clone antibodies, dilutions, and suppliers are listed in table 1 . Assessments of the molecular phenotype were carried out according to HR expression (HR±), HER2 expression, and proliferative status defined by Ki-67 index (with the cutoff of 20% accepted by the 13th St Gallen Consensus Conference ) [26] into four categories: luminal A (HR+/HER2-/low Ki-67 index), luminal B (HR+/HER2±/high Ki-67 index), HER2 overexpression (HR-/ HER2+), and triple negative (HR-/HER2-). Complete phenotype evaluation was obtained for the included cases. Techniques and analyses were based on updated protocols of the American Society of Clinical Oncology/College of American Pathologists [29, 30] . 
Cytological Criteria
All cases were analyzed to assess the presence of five individual cytological criteria: cellularity (analyzed at lower magnification as mild, moderate, or abundant); cellular cohesion (the presence of poorly cohesive cells, showing cellular dissociation, was classified as mild cohesion, while the predominance of cell clusters with marked cellular cohesion was classified as moderate and intense cohesion); necrosis (absent or present, i.e. the presence of numerous neutrophils/tumoral diathesis); nucleoli (classified into inconspicuous, present, and prominent), and nuclear atypia (analyzed considering the nuclear:cytoplasmic ratio, i.e. the dimension of nuclei compared with the diameter of red blood cells and features of the nuclear membrane among neoplastic cells, into the categories mild, moderate, and intense).
Statistical Analysis SAS for Windows (version 9.2) was used. Data are presented as absolute (n) and relative values (%) to assess the association of cytological criteria with histological type and molecular phenotype. The χ 2 test or Fisher's exact test with 95% CI was used. Values of p < 0.05 were considered statistically significant.
Results
From the total of 297 cases selected for this study, 169 cases were included. After complete immunohistochemical evaluation of the TMA slides, applying the surrogate classification of molecular phenotypes accepted by the 13th St Gallen Consensus Conference [26] 
Discussion
Cytological specimens have gained relevance in the era of personalized medicine with the realization of numerous molecular tests -such as DNA extraction techniques, next-generation sequencing, proteomic studies, polymerase chain reaction, and in situ hybridization -made possible, mainly, by the proper fixation and purity of samples [16, 29, 30] . The cell block is a part of the FNA procedure and enables performing immunocytochemistry and molecular tests for further characterization of breast carcinoma, even posteriorly, as it keeps some properties for future ancillary tests, what can be used especially for research purposes [27, 28] . Thus, the intrinsic potential of each sample obtained by the FNA procedure is mainly related with the experience of the cytopathologist to bring together a set of diagnostic, predictive, and prognostic data, using systematic analysis, which includes, at first, cytomorphology [16, 31] . Studies in the literature about cytological criteria associated with molecular phenotypes of breast carcinoma in FNAC are limited to the basal phenotype, whose most relevant criterion described was 'necrosis' [20] . To date, no study has been identified that aimed to evaluate which cytological criteria could predict the luminal phenotype of breast carcinoma.
The investigation of five routinely applied cytological criteria in breast FNAC demonstrated that the luminal phenotype has a tendency to present less cellular samples than nonluminal phenotypes, which was equally well evaluated, at low power, for all stains analyzed (Giemsa, PAP, and HE). The presence of cellular aggregates was also observed, and, statistically, mainly for the luminal A phenotype, cellular cohesion was increased compared to other phenotypes.
Decreased cellular cohesion is a significant characteristic associated with an increased risk of malignancy. Wakasa et al. [35] described a cytological subclassification for breast cytology that showed loss of cellular cohesion; for invasive lobular carcinoma, medullary carcinoma, neuroendocrine carcinoma, and solid papillary carcinoma, this criterion was present in most cases. However, cellular cohesion was not studied for the luminal phenotype of breast carcinoma yet. Regarding the criterion 'absence of necrosis', a significant result to distinguish samples of the luminal A phenotype from other phenotypes was also observed. According to the literature, this phenotype presents mostly a lower nuclear grade, so the presence of extensive necrosis is not expected [8, 23] . For instance, the luminal B phenotype is related to the presence of a higher nuclear grade [33, 34] , which could require a greater evaluation of nuclear details.
The presence of prominent nucleoli was statistically remarkable for either luminal B and nonluminal phenotypes compared with the luminal A phenotype. We are aware, however, about the limitations to establish subjective parameters of size for evaluating nucleoli. In this sense, cytomorphometry in computerized images of breast FN aspirates was described as a highly objective tool [36] . Studies using this application technique for identifying specific phenotypes of breast carcinoma are undoubtedly expected.
There is discussion in the literature about preferred staining methods for breast cytology [37, 38] . Giemsa is referred to be associated with fewer technical problems, superior accuracy, sensitivity, and specificity than HE and PAP staining, which, in turn, is especially useful for evaluating nuclear features along with cytoplasmic differentiation [37, 38] . Comparison of these staining methods was already studied for the evaluation of nodal metastases in breast cancer using intraoperative imprint cytology [37] , but it remains an encouraging issue for future studies in the cytomorphology for phenotype prediction purposes.
The differentiation of the luminal phenotype of breast carcinoma, especially the luminal A phenotype, is of clinical value, since this phenotype presents a better prognosis and is related to lower mortality and a lower rate of metastasis, but it may be associated with lobular carcinoma according to recent studies [39, 40] .
Conclusion
The individual cytological criteria that might indicate the luminal phenotype of breast carcinoma in FNAC were mild-to-moderate cellularity, inconspicuous, present, and nonprominent nucleoli, and mild-to-moderate nuclear atypia. Inconspicuous and nonprominent nucleoli, moderate-to-intense cell cohesion, and absence of necrosis were mainly associated with the luminal A phenotype.
Further research in a larger number of samples, as well as application of new molecular markers possibly related with the luminal phenotype are required to establish which cytological criteria could be predictive and prognostic in breast FNAC. Challenges are considerable, as the luminal phenotype is the most heterogeneous in terms of genetic pathways of growth.
